Clinical trials: Glioblastoma, Adult
Brain and Central Nervous System Tumors
Imatinib Mesylate in Treating Patients With Gliomas
RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and slow the growth of the tumor. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have gliomas.
- Trial name
- NCT00039364
- Testing
- imatinib mesylate
- Where
- 10 sites in Austria, Belgium and 5 more
- Volunteers
- 112 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Brain and Central Nervous System Tumors
Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma
RATIONALE: Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide.
- Trial name
- NCT01026493
- Testing
- temozolomide 60 mg x 21 days, temozolomide 75 mg x 21 days, ABT-888 20 mg x 21 days
- Where
- 17 sites in United States
- Volunteers
- 257 people
- Sponsor
- Radiation Therapy Oncology Group
Brain Tumors, Osteoporosis
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
- Conditions
- Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
- Trial name
- NCT00301873
- Testing
- IV Zometa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Phosphorus 32 in Treating Patients With Glioblastoma Multiforme
RATIONALE: Radioactive drugs such as phosphorus 32 may be able to kill tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of phosphorus 32 in treating patients with glioblastoma multiforme.
- Trial name
- NCT00004129
- Testing
- brachytherapy, phosphorus P32
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Center for Molecular Medicine
Cancer
E-MOSAIC Electronic Tool to Monitor Symptoms
RATIONALE: A hand held electronic tool used to monitor symptoms and assess quality of life may improve communication between patients and their doctors and improve the ability to plan treatment for patients with advanced cancer…
- Trial name
- NCT00477919
- Where
- 7 sites in Switzerland
- Volunteers
- 264 people
- Sponsor
- Swiss Cancer Institute
Brain and Central Nervous System Tumors
Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Glioblastoma Multiforme or Brain Stem Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow or peripheral stem cell transplantation may be able to replace immune cells that were destroyed…
- Trial name
- NCT00002619
- Testing
- filgrastim, carboplatin, thiotepa
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- NYU Langone Health
Advanced Solid Tumor, BRAF V600 Mutation
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
This is a Phase I, First-In-Human, open label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-cancer activity of ABM-1310 in adult patients with locally…
- Trial name
- NCT04190628
- Testing
- ABM-1310, Cobimetinib
- Where
- 8 sites in United States
- Volunteers
- 53 people
- Sponsor
- ABM Therapeutics Corporation
Malignant Glioma of Brain
Study of Acetazolamide With Temozolomide in Adults With Newly Diagnosed or Recurrent Malignant Glioma
This is a Phase I study that examines the rate of dose limiting side effects in patients with malignant astrocytoma treated with combination acetazolamide (ACZ) and temozolomide (TMZ).
- Trial name
- NCT03011671
- Testing
- Acetazolamide, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Chicago
Brain and Central Nervous System Tumors
Vaccine Therapy in Treating Patients With Malignant Glioma
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00068510
- Testing
- therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Giant Cell Glioblastoma, Glioblastoma
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Conditions
- Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
- Trial name
- NCT01149850
- Testing
- bevacizumab, temozolomide, laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Gossypol (AT-101) and Temozolomide With or Without Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy, such as gossypol and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00390403
- Testing
- R-(-)-gossypol acetic acid, temozolomide, gene expression analysis
- Where
- 8 sites in United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
RATIONALE: Erlotinib may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase II trial to study the effectiveness of erlotinib in treating patients who have recurrent or…
- Trial name
- NCT00054496
- Testing
- erlotinib hydrochloride
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- The Cleveland Clinic
Brain and Central Nervous System Tumors
Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI), (done before, during, and after treatment) may help doctors predict a patient's response to treatment…
- Trial name
- NCT00274755
- Testing
- chemotherapy, conventional surgery, magnetic resonance imaging
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- University of California, San Francisco
Glioblastoma
Ph. II Treatment of Adults w Primary Malignant Glioma w Irinotecan + Temozolomide
Objective: To determine activity of combo of Irinotecan + Temozolomide To further characterize any toxicity associated w combo of Irinotecan + Temozolomide
- Trial name
- NCT00616005
- Testing
- Temodar and Irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Duke University
Glioblastoma
Dendritic Cell Vaccination With Standard Postoperative Chemoradiation for the Treatment of Adult Glioblastoma
Effective treatments are desperately needed for glioblastoma (GBM) patients. This phase I clinical trial assesses the safety of a novel personalized dendritic-cell vaccine administered to GBM patients shortly after completing…
- Trial name
- NCT04552886
- Testing
- TH-1 Dendritic Cell Immunotherapy
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Cooper Norcross Health
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Oxaliplatin in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
This phase I/II trial is studying the side effects and best dose of oxaliplatin in treating patients with newly diagnosed glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00005856
- Testing
- oxaliplatin, pharmacological study
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumors
Establishment of a Signature of Circulating microRNA as a Tool to Aid Diagnosis of Primary Brain Tumors in Adults
MIRNA is a prospective multi-center observational study designed to explore 762 plasma microRNAs in patients with malignant CNS tumours: 60 primary glioblastoma (GBM), 20 primary CNS lymphomas and 40 brain metastases in an…
- Trial name
- MIRNA (NCT03630861)
- Where
- France
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain and Central Nervous System Tumors
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
RATIONALE: Imaging procedures that use aminolevulinic acid (ALA) may help find and diagnose residual tumor in participants with grade IV malignant astrocytoma who are undergoing surgery to remove the tumor.
- Trial name
- NCT00752323
- Testing
- aminolevulinic acid, Surgical Resection
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Andrew Sloan, MD
Brain and Central Nervous System Tumors
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003996
- Testing
- carmustine, chemotherapy, cisplatin
- Where
- 19 sites in United States
- Volunteers
- 93 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Glioblastoma
SCH-900105 in Recurrent Glioblastoma
The goal of this clinical research study is to find the highest tolerable dose of SCH 900105 that can be given to patients with glioblastoma before surgery. The safety of this drug will also be studied.
- Trial name
- NCT01189513
- Testing
- SCH 900105
- Sponsor
- M.D. Anderson Cancer Center